Specifications: Test Procedures and Acceptance Criteria ...

1 Federal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health1Dr. Brigitte BrakeBfArM, GermanySpecifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological ProductsICH-GCG ASEAN Training Workshop30th 31stMay 2011, Kuala Lumpur, MalaysiaFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health2 Disclaimer: The information within this presentation is based on the presenter's expertise and experience, and represents the views of the presenter for the purposes of a training workshop. 2011 ICH2 Federal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health3 Session IIIF ederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health4 Issues to be addressed General considerations Regulatory aspects Principles in setting specifications drug substance and drug product Justifications of specifications Specifications vs.

2 IPCs stability aspectsFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health5 Scope of ICH Q6B Applies to proteins and polypeptides, their derivatives, and products of which they are components ( , conjugates). Produced from recombinant or non-recombinant cell-culture expression systems and can be highly purified and characterised using an appropriate set of analytical Procedures . The principles outlined in this document may also apply to other product types such as proteins and polypeptides isolated from tissues and body fluids Does not cover antibiotics, synthetic peptides and polypeptides, heparins, vitamins, cell metabolites, DNA products, allergenic extracts, conventional vaccines, cells, whole blood, and cellular blood components. Federal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health6 Insulin vs.

3 AspirinhGH acetyl salicylic acidInsulinFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health7 Special Features of Biologics Manufacturing process Culture of living organisms, genetic stability , viral safety Harvest: complex matrix dependent on raw-a. starting materials and process conditions Purification: adapted for the desired protein, removal of impurities, avoidance of contaminantsFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health8 Special Features of Biologics Structure complex/ variants ++++ Impurities (DNA, HCP) und contaminants ( viruses) are dependent on the manufacturing process including and raw-and starting materials Analytical methods limited, might be insufficient to comprehensively demonstrate qualityFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health9 Biotech Products -Current Paradigm The process is the product The entire manufacturing process determines the quality of a biotech medicinal product Raw-/starting materials ( cell banks, media, reagents)

4 Fermentation Purification Formulation/Filling The entire manufacturing process should be described and controlled in detail Minor changes may affect quality, safety and efficacy Federal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health10 Biotech Products (rec. Proteins) on the Market Immunmodulators Hormones Monoclonal Antibodies Enzymes Growth Factors Thrombolytics Coagulation Factors VaccinesFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health11 Definition SpecificationSpecifications are critical quality standardsthat are proposed and justified by the manufacturer and approved by the regulatory authorities as conditions of approval. (ICH Q6B) specifications are legally bindingcriteria that a medicinal product must meet set of criteriathat a drug substance and drug product must meet to fulfil pre-defined standards for commercial use assurance that the quality is safe and efficacious over its shelf-lifeFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health12 Definition Specification A specification is defined as a: list of tests, with references to analytical Procedures , with appropriate Acceptance Criteria which are numerical limits, or ranges, or other Criteria for the tests described.

5 It establishes the set of Criteria to which a drug substance, drug product or materials at other stages of its manufacture should conform to be considered acceptable for its intended use. Definition Critical Quality Attribute (CQA) acc. ICH Q8R:A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health13 Definition SpecificationConformance to specification Conformance to specification means that the drug substance and drug product, when tested according to the listed analytical Procedures , will meet the Acceptance Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health14 Implementation of ICH Q6 BImportant.

6 Critically discussed aspects Better understanding of the relative importance/relevanceof specifications as part of a total control strategy Concept of heterogeneityfor biotechproductsFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health15 General Concepts Specifications are one part of a total control strategydesigned to ensure product quality and consistency. Other parts of this strategy include thorough product characterisation during development, upon which many of the specifications are based, adherence to Good Manufacturing Practices, a validated manufacturing process, raw materials testing , in-process testing , stability testing , etc. Specifications are chosen to confirm the quality of the drug substanceand drug product rather than to establish full characterisation and should focuson those molecular and biological characteristics found to be useful in ensuring the safety and efficacyof the Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health16 Specification as part of a total control strategyManufacturing ProcessIPCsBatch resultsSpecificationFacility & EquipmentStability StudiesAnalytic MethodsCharacterisationDEVELOPMENTDrug Substance drug ProductQuality Safety EfficacyFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health17 Control Strategy per ICH Q10 / Q11 Control Strategy.

7 A planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributesrelated to drug substance and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health18CS acc. to ICH Q11 (Step2)A control strategy can include, but is not limited to, thefollowing: Controls on material attributes(including raw materials, starting materials, intermediates, reagents, primary packaging materials for the drug substance, etc.); Procedural Controlsimplicit in the design of the manufacturing process ( , choice of reagents or media, sequence of operations); In-process controls(including in-process tests and process parameters); Controls on drug substance( , release testing ).

8 Federal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health19 Manufacturig Process DevelopmentDrug Substance Critical Quality Attributes A CQAis a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality. Potential drug substance CQAsare used to guide process development. The list of potential CQAs can be modified as drug substance knowledge and process understanding increase. drug substance CQAs typically includethose properties or characteristics that affect identity, purity, biological activity and stabilityFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health20 Manufacturig Process DevelopmentRisk assessment: Linking Material Attributes and Process Parameter to drug Substance CQAs (ICH Q11, step 2) The development program should identify which material attributes( , of raw materials, starting materials, reagents, solvents, process aids, intermediates) and process parameters should be controlled.

9 Risk assessmentcan help identify the material attributes and process parameters with the potential for having an effect on drug substance CQAs. Those material attributes and process parameters that are found to be important should be addressed by the control strategy Using a traditional approach, material specifications and process parameter ranges can be based primarily on batch process history and univariate experiments. An enhanced approachcan lead to a more thorough understanding of the relationship of material attributes and process parameters to CQAs and the effect of Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health21 Manufacturig Process DevelopmentRisk assessment: Linking Material Attributes and Process Parameter to drug Substance CQAs(ICH Q11 step2)Using an enhanced approach, the determination of appropriatematerial specifications and process parameter ranges could followa sequence as shown below: Identify potential sources of process variability; Identify the material attributes and process parameterslikely to have the greatest impact on drug substance quality.

10 This can be based on prior knowledgeand risk assessment tools design and conduct experiments and/or mechanistic studies ( , multivariate design of Experiments, simulations, modelling) to identify and confirm the links and relationships of material attributes and process parameters to drug substance CQAs; Conduct analysis of the datato establish appropriate ranges, including establishment of a design space if desired. Federal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health22 Authorities & Requirements ICH Q1A(R2) stability testing of New Drugds and Substances ICH Q1B stability testing : Photostability of New drug Substances and Products ICH 1C stability testingof New Dosage Forms ICH 1D bracketing and matrixing Designs for Dtability testing of New drug Sustances ICH Q2 Analytical Validation ICH Q4 Q4B Pharmacopoeias ICH Q5A Q5E ICH Q7 GMP ICH Q8 Pharmaceutical Development ICH Q9 Quality Risk Mangement ICH Q10 Pharmaceutical Quality Systems ICHQ11 Development and Manufacture of drug SubstanceFederal Institute for Drugsand Medical DevicesThe BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health23 ICH Guidelines Bio ICH Q5A: Viral Safety ICH Q5B: Genetic stability ICH Q5C.